NVE Corporation — FY2023 Form 10-K
Reporting period: Fiscal year ended March 31, 2023, compared with fiscal 2022. NVE develops and sells spintronics-based sensors, couplers, and related products, and also earns contract research and development revenue. Its financial statements were audited; the auditor issued an unqualified opinion and reported no critical audit matters.
Financial performance and position
| Metric | FY2023 / March 31, 2023 | FY2022 / March 31, 2022 |
|---|---|---|
| Revenue | $38.25 million | $26.99 million |
| Product sales | $37.20 million | $25.87 million |
| Contract R&D revenue | $1.06 million | $1.12 million |
| Gross profit / margin | $30.19 million / 78.9% | $20.72 million / 76.8% |
| Operating income / margin | $25.64 million / 67.0% | $16.33 million / 60.5% |
| Net income / net margin | $22.69 million / 59.3% | $14.51 million / 53.8% |
| Diluted earnings per share | $4.70 | $3.00 |
| Operating cash flow | $19.09 million | $12.50 million |
| Capital expenditures | $0.94 million | $0.48 million |
| Cash and cash equivalents | $1.67 million | $10.45 million |
| Marketable securities | $52.54 million | $51.91 million |
| Total liabilities | $2.18 million | $2.90 million |
Debt and liquidity: The filing reports no borrowings or interest-bearing debt. Current assets were $30.79 million and current liabilities were $1.83 million. Cash declined $8.78 million during the year as operating cash flow was more than offset by dividends, securities purchases, and other investing activity. Cash dividends paid were $19.32 million; the company also repurchased $20,700 of stock.
Material changes and management commentary
- Revenue increased 41.7%, driven by a 43.8% rise in product sales as purchases increased among existing customers and most markets and product lines grew. Contract R&D revenue fell 5.6% following completion of certain contracts.
- Gross margin rose to 78.9%, which management attributed mainly to increased production scale and higher prices, partly offset by higher material and labor costs.
- Total expenses rose 3.5%. R&D expense declined 11.7% as resources shifted toward revenue-generating activities; selling, general, and administrative expense increased 33.6%, mainly due to staffing and compensation.
- Interest income increased 23.7% with higher average rates and available-for-sale securities. A $197,008 investment tax credit associated with the CHIPS and Science Act contributed to a lower effective tax rate; management cautioned the fiscal 2023 rate may not indicate future rates.
- Management reported new or improved DC-to-DC converters and TMR sensors, and continued development of higher-sensitivity sensors and antitamper MRAM. No quantified revenue or earnings guidance was provided.
Outlook, risks, and unusual items
- Customer concentration: One customer represented 22% of fiscal 2023 revenue, down from 25%; another customer that represented 11% in fiscal 2022 was below the 10% disclosure threshold in fiscal 2023. The filing identifies Abbott, Sonova, other medical-device manufacturers, and distributors among significant customers. The Abbott Supplier Partnering Agreement expires December 31, 2023; renewal terms are uncertain.
- Supply and production: NVE depends on single-source suppliers for some wafers, materials, and packaging. Semiconductor shortages, vendor interruptions, foreign sourcing, tariffs, and labor constraints could delay production or reduce sales. Management also cited wage inflation and increased labor competition.
- Investments: Marketable securities were approximately 76% of total assets. Corporate bonds had $1.55 million of gross unrealized losses at year-end, compared with $0.64 million a year earlier. The company did not consider the securities impaired, but changes in rates, credit conditions, or liquidity needs could affect fair value and cash availability.
- Dividends: The company declared $4.00 per share for fiscal 2023 and announced a further $1.00-per-share dividend after year-end. Management states dividends may be changed or discontinued and acknowledges recent declared dividend amounts may not be sustainable, as they generally exceed current operating cash flow.
- Other disclosed exposures include competition and pricing pressure, medical-device product liability and recall risks, customer qualification requirements, foreign operations, cybersecurity, and climate-related or other disruptions to energy and suppliers. No material pending legal proceedings were identified.
Important facts for investors to verify
- Customer-level revenue concentration and the status and renewal terms of the Abbott agreement before its December 2023 expiration.
- Whether operating cash flow can support dividends, capital spending, and working-capital needs; review the board’s subsequent dividend decisions.
- Portfolio composition, maturities, credit quality, unrealized losses, and potential sensitivity of the $52.54 million securities balance to interest rates and credit conditions.
- Whether wafer, packaging, and labor constraints affect delivery capacity, costs, or customer demand.
- Actual adoption and commercial contribution of the new products and ongoing sensor and MRAM development; the filing provides no quantified forward guidance.